Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retrospective, Landmark Analysis of Long-term Adult Morbidity Following Allogeneic HSCT for Inborn Errors of Immunity in Infancy and Childhood.
Day JW, Elfeky R, Nicholson B, Goodman R, Pearce R, Fox TA, Worth A, Booth C, Veys P, Carpenter B, Hough R, Gaspar HB, Titman P, Ridout D, Workman S, Hernandes F, Sandford K, Laurence A, Campbell M, Burns SO, Morris EC. Day JW, et al. Among authors: morris ec. J Clin Immunol. 2022 Aug;42(6):1230-1243. doi: 10.1007/s10875-022-01278-6. Epub 2022 May 17. J Clin Immunol. 2022. PMID: 35579633 Free PMC article.
Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation.
Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Parker A, Pettengell R, Milligan D, Morris EC, Goldstone AH, Linch DC, Mackinnon S. Thomson KJ, et al. Among authors: morris ec. Bone Marrow Transplant. 2008 May;41(9):765-70. doi: 10.1038/sj.bmt.1705977. Epub 2008 Jan 14. Bone Marrow Transplant. 2008. PMID: 18195684
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
Mead AJ, Thomson KJ, Morris EC, Mohamedbhai S, Denovan S, Orti G, Fielding AK, Kottaridis PD, Hough R, Chakraverty R, Linch DC, Mackinnon S, Peggs KS. Mead AJ, et al. Among authors: morris ec. Blood. 2010 Jun 24;115(25):5147-53. doi: 10.1182/blood-2010-01-265413. Epub 2010 Apr 6. Blood. 2010. PMID: 20371745 Free article.
Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, Morris E, Orchard K, Rule S, Russell N, Craddock C, Marks DI; Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT). Cook G, et al. Biol Blood Marrow Transplant. 2010 Oct;16(10):1419-27. doi: 10.1016/j.bbmt.2010.04.006. Epub 2010 Apr 24. Biol Blood Marrow Transplant. 2010. PMID: 20399879 Free article.
T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.
Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G, Bloor AJ, Clark F, Kazmi M, Linch DC, Chakraverty R, Peggs KS, Mackinnon S. Thomson KJ, et al. Among authors: morris ec. J Clin Oncol. 2010 Aug 10;28(23):3695-700. doi: 10.1200/JCO.2009.26.9100. Epub 2010 Jul 6. J Clin Oncol. 2010. PMID: 20606089 Clinical Trial.
Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.
Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC, Hough R, Morris EC, Fielding A, Chakraverty R, Thomson KJ, Mackinnon S. Peggs KS, et al. Among authors: morris ec. J Clin Oncol. 2011 Mar 10;29(8):971-8. doi: 10.1200/JCO.2010.32.1711. Epub 2011 Jan 31. J Clin Oncol. 2011. PMID: 21282545
152 results